Siren L.L.C. Sells 5,744 Shares of Bicara Therapeutics Inc. $BCAX

Siren L.L.C. decreased its position in Bicara Therapeutics Inc. (NASDAQ:BCAX) by 0.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,267,083 shares of the company’s stock after selling 5,744 shares during the period. Bicara Therapeutics comprises approximately 2.5% of Siren L.L.C.’s holdings, making the stock its 11th largest holding. Siren L.L.C. owned 0.06% of Bicara Therapeutics worth $42,570,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the company. Red Tree Management LLC bought a new stake in shares of Bicara Therapeutics during the fourth quarter valued at approximately $55,230,000. Deep Track Capital LP boosted its stake in Bicara Therapeutics by 151.0% during the fourth quarter. Deep Track Capital LP now owns 2,000,000 shares of the company’s stock worth $34,840,000 after buying an additional 1,203,148 shares in the last quarter. Acorn Capital Advisors LLC bought a new stake in Bicara Therapeutics in the 4th quarter valued at $11,208,000. Wellington Management Group LLP raised its stake in shares of Bicara Therapeutics by 84.0% in the 1st quarter. Wellington Management Group LLP now owns 1,394,676 shares of the company’s stock valued at $18,173,000 after buying an additional 636,708 shares in the last quarter. Finally, Braidwell LP lifted its holdings in shares of Bicara Therapeutics by 20.7% during the 4th quarter. Braidwell LP now owns 2,000,659 shares of the company’s stock worth $34,851,000 after acquiring an additional 343,059 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Wells Fargo & Company raised shares of Bicara Therapeutics from an “underweight” rating to an “equal weight” rating and set a $8.00 target price on the stock in a research note on Friday, May 23rd. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, August 12th. Piper Sandler initiated coverage on Bicara Therapeutics in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 target price for the company. Wall Street Zen downgraded Bicara Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Finally, HC Wainwright lowered their price target on Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $32.25.

Bicara Therapeutics Trading Down 0.9%

NASDAQ BCAX opened at $11.91 on Friday. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $28.09. The company has a 50 day moving average of $10.59 and a 200-day moving average of $11.89. The firm has a market cap of $649.85 million and a price-to-earnings ratio of -3.76.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.04. On average, analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.